Cellosaurus logo
expasy logo

Cellosaurus Marimo (CVCL_6992)

[Text version]
Cell line name Marimo
Synonyms MARIMO
Accession CVCL_6992
Resource Identification Initiative To cite this cell line use: Marimo (RRID:CVCL_6992)
Comments Characteristics: This cell line is independent of the CALR-MPL-JAK2-STAT5 pathway.
Doubling time: 25-28 hours (PubMed=9406575).
Omics: Deep quantitative phosphoproteome analysis.
Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
Sequence variations
  • Mutation; HGNC; 1455; CALR; Simple; p.Leu367Metfs*43 (c.1099_1159del61); Zygosity=Heterozygous (PubMed=25249012; PubMed=30115971).
  • Mutation; HGNC; 7217; MPL; Simple; p.Ser505Asn (c.1514G>A); ClinVar=VCV000014163; Zygosity=Heterozygous (PubMed=30115971).
  • Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=30115971).
  • Mutation; HGNC; 11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Homozygous (PubMed=30115971).
Disease Therapy-related acute myeloid leukemia (NCIt: C8252)
Therapy related acute myeloid leukemia and myelodysplastic syndrome (ORDO: Orphanet_86846)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 68Y
Category Cancer cell line

PubMed=9406575; DOI=10.1016/S0165-4608(97)00017-4
Yoshida H., Kondo M., Ichihashi T., Hashimoto N., Inazawa J., Ohno R., Naoe T.
A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification.
Cancer Genet. Cytogenet. 100:21-24(1998)

Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=21552520; DOI=10.1371/journal.pone.0019169
Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A., Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P., Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.
Survey of activated FLT3 signaling in leukemia.
PLoS ONE 6:E19169-E19169(2011)

PubMed=25249012; DOI=10.1038/leu.2014.285
Kollmann K., Nangalia J., Warsch W., Quentmeier H., Bench A., Boyd E., Scott M., Drexler H.G., Green A.R.
MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.
Leukemia 29:494-497(2015)

PubMed=30115971; DOI=10.1038/s41375-018-0234-6
Han L.-J., Czech J., Maurer A., Brummendorf T.H., Chatain N., Koschmieder S.
Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR-MPL-JAK2-STAT5 pathway.
Leukemia 32:2087-2090(2018)

Cell line databases/resources cancercelllines; CVCL_6992
Encyclopedic resources Wikidata; Q54904030
Polymorphism and mutation databases Cosmic; 787448
Cosmic; 975266
Cosmic; 1012083
Cosmic; 1281324
Cosmic; 1465956
Cosmic; 1465959
Cosmic; 2306195
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number19